drugset / Trial / NCT06055816

Gemcitabine Combined With Endostar and Envafolimab in Elderly Patients With Locally Advanced Nasopharyngeal Carcinoma

NCT06055816

Phase 2 Recruiting 40 enrolled Zhejiang Cancer Hospital
NaSingle-groupOpen-labelTreatment

Summary

Gemcitabine Combined With Endostar and Envafolimab in Elderly Patients With Locally Advanced Nasopharyngeal Carcinoma

Timeline

Start
2023-09-28
Primary completion
2024-09-30
Completion
2028-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Endostar Protein / enzyme biologic 150 mg
Subject Envafolimab Monoclonal antibody 240 mg
Subject Gemcitabine Small molecule 1000 mg/m2